Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study
2021; Nature Portfolio; Volume: 27; Issue: 6 Linguagem: Inglês
10.1038/s41591-021-01330-9
ISSN1546-170X
AutoresJingxin Li, Ai‐Min Hui, Xiang Zhang, Yumei Yang, Rong Tang, Huayue Ye, Rui‐Ru Ji, Mei Lin, Zhongkui Zhu, Özlem Türeci, Eleni Lagkadinou, Siyue Jia, Hongxing Pan, Fuzhong Peng, Zhilong Ma, Zhenggang Wu, Xiling Guo, Yunfeng Shi, Alexander Muik, Uǧur Şahin, Li Zhu, Fengcai Zhu,
Tópico(s)Immunotherapy and Immune Responses
Referência(s)